Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs)
Purpose of Review The introduction of newer anticoagulants requires clinicians to fully appreciate, interpret, and correctly apply the use of coagulation assays, such as the prothrombin time (PT), activated partial thromboplastin time (APTT), and anti-factor Xa assays. For oral vitamin K antagonists, the international normalized ratio (INR) is a predictor of anticoagulation intensity. However, for direct oral anticoagulants (DOACs), the PT or INR and APTT are unable to quantify the level of anticoagulation intensity as there is a poor correlation between plasma concentration of DOAC with these routine coagulation assays and that significant anticoagulant effect may still be present despite normal or near normal results for these routine assays. Recent Findings In the USA, there are 5 DOACs available including dabigatran, a direct thrombin inhibitor and 4 direct factor Xa inhibitors (FXaI), each with varying indications, doses, pharmacodynamic, and pharmacokinetic characteristics. A thorough understanding of these properties aids in the management of the periprocedural or bleeding patient. Summary In this first section of this manuscript, we will review the laboratory tests that are commonly performed for assessing a patient’s coagulation status with known DOAC exposure. The second section will describe 3 real-world challenging case studies in DOAC-treated patients, with a focus on presenting clinical queries, interpretation of baseline laboratory tests with interpretations, followed by the case discussion to combine interpretation of appropriate laboratory tests with clinical patient considerations in an effort to guide clinical decision-making..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Current pharmacology reports - 6(2020), 5 vom: 24. Aug., Seite 241-259 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rimsans, Jessica [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Andexanet |
| doi: |
10.1007/s40495-020-00232-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR040911535 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR040911535 | ||
| 003 | DE-627 | ||
| 005 | 20230520011704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40495-020-00232-7 |2 doi | |
| 035 | |a (DE-627)SPR040911535 | ||
| 035 | |a (SPR)s40495-020-00232-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Rimsans, Jessica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose of Review The introduction of newer anticoagulants requires clinicians to fully appreciate, interpret, and correctly apply the use of coagulation assays, such as the prothrombin time (PT), activated partial thromboplastin time (APTT), and anti-factor Xa assays. For oral vitamin K antagonists, the international normalized ratio (INR) is a predictor of anticoagulation intensity. However, for direct oral anticoagulants (DOACs), the PT or INR and APTT are unable to quantify the level of anticoagulation intensity as there is a poor correlation between plasma concentration of DOAC with these routine coagulation assays and that significant anticoagulant effect may still be present despite normal or near normal results for these routine assays. Recent Findings In the USA, there are 5 DOACs available including dabigatran, a direct thrombin inhibitor and 4 direct factor Xa inhibitors (FXaI), each with varying indications, doses, pharmacodynamic, and pharmacokinetic characteristics. A thorough understanding of these properties aids in the management of the periprocedural or bleeding patient. Summary In this first section of this manuscript, we will review the laboratory tests that are commonly performed for assessing a patient’s coagulation status with known DOAC exposure. The second section will describe 3 real-world challenging case studies in DOAC-treated patients, with a focus on presenting clinical queries, interpretation of baseline laboratory tests with interpretations, followed by the case discussion to combine interpretation of appropriate laboratory tests with clinical patient considerations in an effort to guide clinical decision-making. | ||
| 650 | 4 | |a Direct oral anticoagulants |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Laboratory testing |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dabigatran |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rivaroxaban |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Apixaban |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Edoxaban |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Betrixaban |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ecarin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anti-FXa |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Thrombin generation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Andexanet |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dilute thrombin time |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Thrombin time |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Smythe, Maureen A |e verfasserin |4 aut | |
| 700 | 1 | |a Gosselin, Robert C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmacology reports |d Berlin [u.a.] : Springer, 2015 |g 6(2020), 5 vom: 24. Aug., Seite 241-259 |w (DE-627)SPR036533181 |w (DE-600)2809351-3 |x 2198-641X |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2020 |g number:5 |g day:24 |g month:08 |g pages:241-259 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40495-020-00232-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 6 |j 2020 |e 5 |b 24 |c 08 |h 241-259 | ||